PT  - JOURNAL ARTICLE
AU  - Hwang, Yeon Mi
AU  - Wei, Qi
AU  - Piekos, Samantha N.
AU  - Vemuri, Bhargav
AU  - Molani, Sevda
AU  - Mease, Philip
AU  - Hood, Leroy
AU  - Hadlock, Jennifer J.
TI  - Maternal-fetal outcomes in patients with immune mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system
AID  - 10.1101/2023.08.07.23293726
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.07.23293726
4099  - http://medrxiv.org/content/early/2023/08/09/2023.08.07.23293726.short
4100  - http://medrxiv.org/content/early/2023/08/09/2023.08.07.23293726.full
AB  - Background Immune-mediated inflammatory diseases (IMIDs) are likely to complicate maternal health. However, literature data on patients with IMIDs undergoing pregnancy is scarce and often overlooks the impact of comorbidities.Methods We investigated 12 selected IMIDs: psoriasis, inflammatory bowel disease, rheumatoid arthritis, spondyloarthritis, multiple sclerosis, systemic lupus erythematosus, psoriatic arthritis, antiphospholipid syndrome, Sjögren’s syndrome, vasculitis, sarcoidosis, systemic sclerosis. We characterized patients with IMIDs prior to pregnancy (IMIDs group) based on pregnancy/maternal characteristics, comorbidities, and pre-pregnancy/prenatal immunomodulatory medications (IMMs) prescription patterns. We 1:1 propensity score matched the IMIDs cohort with people who had no IMID diagnoses prior to pregnancy (non-IMIDs cohort). Outcome measures were preterm birth (PTB), low birth weight (LBW), small for gestational age (SGA), and cesarean section.Findings The prevalence rate of pregnancy occurring with people with a previous IMID diagnosis has doubled in the past ten years. We identified 5,784 patients with IMIDs. 17% of the IMIDs group had at least one prenatal IMM prescription. Depending on the type of IMM, from 48% to 70% of the patients taking IMMs before pregnancy continued them throughout pregnancy. Patients with IMIDs had similar but slightly increased risks of PTB (Relative risk (RR)=1·1[1·0, 1·3]), LBW (RR=1·2 [1·0,1·4]), SGA (RR=1·1 [1·0,1·2]), and cesarean section (RR=1·1 [1·1,1·2]) compared to a matched cohort of people without IMIDs. Out of the 12 selected IMIDs, three for PTB, one for LBW, two for SGA, and six for cesarean section had results supporting increased risk.Interpretation The association between IMIDs and the increased risk of adverse pregnancy outcomes depend on both the nature of the IMID and the presence of comorbidities.Funding NIHCompeting Interest StatementYH, SNP, BV, and SM declare no conflict of interest. PM receives grant funding from Abbvie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Pfizer, Novartis, Sun Pharma, Janssen, and UCB. PM consults for Abbvie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Imagine, Moonlake Pharama, Novartis, Sun Pharma, Union Chimique Belge. JH has received research funding from Pfizer, Novartis, Janssen, Gilead and Bristol Myers Squibb (paid to institute). QW has been funded in part by Pfizer, Novartis, and Janssen (paid to the institute). LH is scientific advisors for Sera Prognostics, a pregnancy diagnostics company. Sera Prognostics is not associated with this study or any of the findings. Funding StatementSupport was provided in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through the Biomedical Data Translator program, award #3OT2TR00344301S1. Any opinions expressed in this document are those of the Translator community at large and do not necessarily reflect the views of NCATS, individual Translator team members, or affiliated organizations and institutions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures were reviewed and approved by the Institutional Review Board at the Providence Health and Services and affiliates through expedited review on 11-04-2020 (study number STUDY2020000196). Consent was waived because disclosure of protected health information for the study involved no more than minimal risk to the privacy of individuals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesResults have been aggregated and reported within this paper to the extent possible while maintaining privacy from personal health information (PHI) as required by law. All data is archived within Providence Health Services and Affiliates systems in a HIPAA-secure audited compute environment to facilitate verification of study conclusions. All clinical logic for data extraction has been shared within the paper and supplemental materials. Code is publicly available at https://github.com/Hadlock-Lab/IMIDs_Maternity_Stats https://github.com/Hadlock-Lab/IMIDs_Maternity_Stats